<DOC>
	<DOCNO>NCT01034202</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure drug ) pharmacodynamics ( effect ) NNC126-0083 compare Norditropin速 SimpleXx速 placebo healthy volunteer</brief_summary>
	<brief_title>Dose Study Healthy Males Investigating Safety , Pharmacokinetics Pharmacodynamics NNC126-0083 Compared Norditropin速 SimpleXx速</brief_title>
	<detailed_description />
	<criteria>Healthy , nonsmoking male subject Body Mass Index ( BMI ) 19.0 28.0 kg/m2 , inclusive Body weight max . 100 kg A history presence cancer , diabetes , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disease Carrier Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody Positive result test HIV ( Human Immunodeficiency Virus ) antibodies Any clinically significant abnormal haematology biochemistry screen test , judge physician Clinically significant abnormal ECG ( ElectroCardioGram ) screen evaluate physician A significant history alcoholism drug/chemical abuse , positive result urine drug/alcohol screen , consume 28 unit alcohol per week ( one unit alcohol equal 250 ml beer lager , 1 glass wine , 20 ml spirit ) Habitual smoking , i.e daily smoke 7 cigarettes/week Mental incapacity language barrier preclude adequate understanding cooperation , unwilling participate trial , opinion general practitioner Investigator participate trial Surgery trauma significant blood loss within last 2 month prior dose</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>